Clinical Trials
2 trialsNCT03587740 2026-05-18
ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04439110 2026-05-08
Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)
National Cancer Institute (NCI)
Phase 2 Active not recruiting